Cervical Disc Arthroplasty vs. ACDF: What the Medical Literature Reports on Long-Term Outcomes

Cervical disc arthroplasty (CDA), also called cervical artificial disc replacement, replaces a removed cervical intervertebral disc with a motion-preserving implant; anterior cervical discectomy and fusion (ACDF) removes disc material and stabilizes the level through fusion. This article summarizes what peer-reviewed randomized trials, long-term follow-up studies, systematic reviews, meta-analyses, FDA labeling, and current clinical practice report about the procedures, their studied populations, comparative outcomes, and evidence limits. It is intended as an educational overview and does not evaluate, address, or offer opinion on any individual patient, provider, or matter.

How the procedures differ

Both procedures approach the cervical spine from the front and remove disc material that is part of a compressive lesion. In ACDF, the treated segment is stabilized while the vertebrae fuse. In CDA, an artificial disc is placed with the goal of maintaining movement at that segment. The devices differ in design, materials, and approved labeling, and motion preservation is not the same as a guarantee that full motion will remain after surgery.

The randomized literature compares the procedures in selected groups with cervical degenerative disc disease, most often with one or two treated levels. Published endpoints include disability, neck and arm pain, neurological status, composite treatment success, radiographic changes at adjacent segments, adverse events, and later operations. These endpoints answer different questions. A radiographic change does not by itself establish symptoms, and a composite success measure combines components chosen by the study protocol.

Populations studied and device-specific selection

The principal comparative evidence comes from prospective randomized investigational-device trials and their postapproval follow-up. These studies generally enrolled skeletally mature adults with symptomatic cervical disc disease at one or two contiguous levels, commonly involving radiculopathy, myelopathy, or both. The details of the treated levels, implants, control fusion procedures, and enrollment criteria were not identical across trials.

FDA indications and labeling are specific to each artificial-disc device. A patient-selection review describes common trial criteria such as one or two contiguous levels from C3 through C7 and identifies conditions often excluded across device studies, including substantial instability, severe facet degeneration, poor bone quality, marked deformity, or advanced spondylosis. The review also emphasizes that criteria are similar but not identical across products. These descriptions summarize the evidence base and labeling; they do not establish a universal eligibility rule.

Results from on-label one- or two-level trials should not be assumed to establish outcomes for every cervical diagnosis, implant, or construct. More-than-two-level treatment, hybrid constructs, revision settings, and populations excluded from pivotal trials have less comparative evidence. Device labeling and the actual study populations therefore matter when interpreting reported averages.

Patient-reported outcomes in comparative studies

Randomized trials report that both CDA and ACDF can produce sustained improvements in disability and pain measures among enrolled participants. Long-term reports from one-level and two-level trials have found maintained improvement in both groups, while some device-specific trials report higher composite success or better average scores after CDA. Such results are tied to the device, eligibility criteria, study endpoints, and follow-up sample used in each trial.

Systematic reviews and meta-analyses of randomized trials with five or more years of follow-up generally find a mixed pattern rather than a difference on every measure. A review of 14 randomized trials reported advantages for CDA on Neck Disability Index and neurological success, while some physical-health scores favored ACDF; pooled neck- and arm-pain changes were not significantly different. A separate 10-year systematic review and meta-analysis of six comparative studies found statistically better average Neck Disability Index and pain scores after CDA, but the differences did not meet the review's thresholds for minimal clinical importance. It also found no significant difference in neurological success.

These findings illustrate why statistical significance and clinical importance are reported separately. A small average difference can reach statistical significance in a pooled sample without representing a large functional difference. Conversely, lack of a statistically significant difference does not by itself demonstrate that two procedures are equivalent. Reviews may also reach different conclusions because they combine different devices, levels, study designs, and outcome definitions.

Across long-term comparative reviews, recurring findings include:

• —Sustained improvements in disability and pain measures after both CDA and ACDF in selected trial populations.
• —CDA advantages on some pooled disability, neurological-success, or composite endpoints, but not on every measure.
• —No consistent pooled difference in average neck- and arm-pain change across the randomized-trial reviews summarized above.
• —Some score differences that are statistically significant but below minimal clinically important difference thresholds.

Motion preservation and adjacent segments

Maintaining motion at the treated level is the biomechanical rationale for CDA. Long-term trial reports commonly show continued segmental movement in the arthroplasty group, while fusion procedures aim for lack of movement across the treated level. The comparison does not mean that every arthroplasty retains its intended range of motion or that motion preservation alone predicts symptoms or future adjacent-level disease.

The adjacent-segment literature distinguishes radiographic degeneration from symptomatic disease and from a later operation at an adjacent level. A meta-analysis of randomized trials with five- to ten-year follow-up reported lower radiographic adjacent-segment degeneration after CDA at some follow-up points, but not a significant difference at ten years. The same review reported fewer operations for symptomatic adjacent-level disease in some longer-term intervals. Individual trials and other reviews report differing rates, and adjacent-level pathology has multiple potential contributors, including the natural history of degeneration.

Secondary procedures and adverse events

Several long-term randomized trial reports and pooled analyses describe fewer secondary procedures after CDA than after ACDF in their selected study populations. A two-level randomized investigational-device trial reported fewer index-level secondary procedures in the arthroplasty arm at ten years and also reported fewer adjacent-level procedures. A different ten-year follow-up study found lower cumulative subsequent-surgery and adjacent-level surgery rates after CDA, although its later follow-up came from consenting participants at a subset of high-enrolling centers rather than every original trial site.

Meta-analytic findings on adverse events are not uniform. The five-to-ten-year review of randomized trials did not find a significant difference in overall adverse-event rates, while the separate ten-year synthesis reported fewer adverse events after CDA. Implant-specific events and the components of a composite endpoint also differ across studies. The literature therefore supports describing a recurring reduction in some secondary-procedure measures, alongside variation in adverse-event results, rather than treating all long-term comparisons as identical.

Long-term studies often report fewer secondary operations after cervical disc arthroplasty in selected trial populations, while differences in pain and function are endpoint-dependent and may be smaller than clinical-importance thresholds.

Limits of the comparative evidence

The evidence base has several recurring constraints. Pivotal trials tested particular devices against particular fusion methods, so pooled findings do not make every implant interchangeable. Trials enrolled selected populations under device-specific criteria, and the results may not generalize to diagnoses, levels, or health factors that were excluded. Long-term studies also have follow-up loss or rely on postapproval participants, which can affect how well the analyzed group represents the original randomized cohort.

Reviews vary in their inclusion of randomized trials and comparative cohorts, the number of levels, the duration of follow-up, and the definition of success. Adjacent-segment degeneration, symptomatic adjacent-level disease, and reoperation are related but distinct measures. Patient-reported scores, neurological success, adverse events, and later procedures likewise capture different aspects of outcome. These design differences help explain why one review may find a statistically significant advantage for CDA on a particular endpoint while another reports no difference or an effect below a minimal clinically important threshold.

Summary of the published evidence

Across prospective randomized device trials, long-term follow-up reports, systematic reviews, meta-analyses, and FDA labeling, several themes recur. CDA is designed to preserve motion at a treated cervical level, whereas ACDF stabilizes that level through fusion. Both procedures show sustained improvement in selected trial populations. Long-term pooled results sometimes favor CDA on disability, neurological success, or secondary procedures, but differences in pain, function, radiographic adjacent-segment change, and adverse events are not uniform across reviews. Some average score differences are statistically significant without meeting thresholds for minimal clinical importance. A reduction in later surgery is reported in several long-term comparisons, but estimates depend on device, study population, number of levels, follow-up, and endpoint. FDA indications are product-specific, and the randomized evidence is concentrated in selected one- or two-level populations. The literature therefore describes comparative patterns and limits rather than a universal result across all patients or devices.

This overview is educational. It is not medical advice, does not evaluate any specific patient or matter, and does not substitute for review of the primary peer-reviewed sources.